Stock Day Media

U.K. MHRA Clears CytoDyn to File its BLA for Leronlimab as One Injection per Week for Combination HIV Therapy

October 27, 2020October 27, 2020 Stock Day Media 130 Views BLA, cydy, HIVtherapy, Leronlimab, oneinjection, UK

VANCOUVER, Washington, Oct. 26, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing

BioTech

CytoDyn Appoints Chiral Pharma to Secure Leronlimab for Local FDA Approval in Philippines

October 13, 2020October 13, 2020 Stock Day Media 221 Views chiralpharma, cydy, cytodyn, FDA, Leronlimab, philippines

VANCOUVER, Washington, Oct. 12, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing

BioTech

CytoDyn to Hold Conference Call on September 16 to Provide Update on Discussions with FDA and MHRA for COVID-19 and FDA Meeting on BLA Filing

September 11, 2020September 11, 2020 Stock Day Media 706 Views BLA, covid19, cydy, cytodyn, FDA

VANCOUVER, Washington, Sept. 10, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing

BioTech

CytoDyn Announces Upcoming Retirement of Dr. David Welch from its Board of Directors

August 19, 2020August 19, 2020 Stock Day Media 205 Views cydy, dr.welch

VANCOUVER, Washington, Aug. 18, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing

BioTech

CytoDyn Announces Clinically Significant Top-line Results from its Phase 2 Trial in Mild-to-Moderate COVID-19 Patients

August 11, 2020August 11, 2020 Stock Day Media 355 Views coronavirus, covid19, cydy, cytodyn

Primary endpoint shows early clinical improvement in symptom score at Day 3 in patients receiving leronlimab Leronlimab also demonstrated statistically

BioTech

CytoDyn Seeks UK Approval of Leronlimab for HIV and COVID-19

August 7, 2020August 7, 2020 Stock Day Media 281 Views covid19, cydy, cytodyn, hiv, Leronlimab

BLA-type submission planned this month in U.K. for HIV combination therapy with 350 mg weekly dose• COVID-19 Phase 2 topline report

BioTech

CytoDyn Completes Non-dilutive $28.5 Million Convertible Note Financing with Conversion Rate at $10.00 Per Share without Warrants

July 30, 2020July 30, 2020 Stock Day Media 889 Views convertibledebt, cydy, cytodyn

VANCOUVER, Washington, July 29, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing

BioTech

Impressive Results From CytoDyn’s Phase 2 Covid-19 Trial

July 21, 2020July 21, 2020 Stock Day Media 456 Views covid19trial, cydy, cytodyn

39% of Patients in Placebo Arm Had SAEs as Compared to Only 14% of Patients in Leronlimab Arm Had SAEs,

BioTech

CytoDyn Announces Execution of Exclusive Agreement with American Regent for Distribution and Supply of Leronlimab for Treatment of COVID-19 in United States

July 6, 2020July 6, 2020 Stock Day Media 937 Views covid19, cydy, cytodyn, Leronlimab

This Agreement will allow for immediate distribution of leronlimab to patients for the treatment of COVID-19 upon successful completion of

BioTech

CytoDyn Releases Mechanism of Action Animation for Leronlimab in Immuno-Oncology

July 2, 2020July 2, 2020 Stock Day Media 897 Views cydy, Immuno-Oncology, Leronlimab, mechanism

VANCOUVER, Washington, July 02, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company

cydy

U.K. MHRA Clears CytoDyn to File its BLA for Leronlimab as One Injection per Week for Combination HIV Therapy

CytoDyn Appoints Chiral Pharma to Secure Leronlimab for Local FDA Approval in Philippines

CytoDyn’s Phase 2 Study of Leronlimab for Mild-to-Moderate COVID-19 Selected for Oral Presentation at the Special isirv-AVG Virtual Conference on ‘Therapeutics for COVID-19’

CytoDyn to Hold Conference Call on September 16 to Provide Update on Discussions with FDA and MHRA for COVID-19 and FDA Meeting on BLA Filing

After Several Months of Providing Requested Information About Manufacturing and Safety of Leronlimab, U.K.’s MHRA Accepts CytoDyn’s Request to Enroll in its Current Phase 3 Trial for COVID-19 Patients with Severe-to-Critical Symptoms

CytoDyn Announces Upcoming Retirement of Dr. David Welch from its Board of Directors

CytoDyn Announces Clinically Significant Top-line Results from its Phase 2 Trial in Mild-to-Moderate COVID-19 Patients

CytoDyn Seeks UK Approval of Leronlimab for HIV and COVID-19

CytoDyn Completes Non-dilutive $28.5 Million Convertible Note Financing with Conversion Rate at $10.00 Per Share without Warrants

Impressive Results From CytoDyn’s Phase 2 Covid-19 Trial

CytoDyn Announces Execution of Exclusive Agreement with American Regent for Distribution and Supply of Leronlimab for Treatment of COVID-19 in United States

CytoDyn Releases Mechanism of Action Animation for Leronlimab in Immuno-Oncology